Skip to main content

Beneficial ownership — 13D / 13G

87,240 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Karpus Management, Inc. GLST Global Star Acquisition, Inc. Class A Common Stock 13G/A 4.13% 3y
WELLINGTON MANAGEMENT GROUP LLP RUSHA Rush Enterprises Inc Tx 13G/A 10.05% 3y
Karpus Management, Inc. KTF Dws Municipal Income Trust 13G/A 1.79% 3y
WELLINGTON MANAGEMENT GROUP LLP SP SP Plus Corporation 13G/A 2.45% 3y
Karpus Management, Inc. VTN Invesco Trust for Investment Grade New York Municipals 13G/A 0.98% 3y
JANUS HENDERSON GROUP PLC SKIN SkinHealth Systems Inc. 13G/A 10.1% 3y
WELLINGTON MANAGEMENT GROUP LLP ACH Accendra Health Inc 13G/A 4.76% 3y
BAILLIE GIFFORD & CO NVCR NovoCure Ltd 13G/A 4.77% 3y
WELLINGTON MANAGEMENT GROUP LLP RVMD Revolution Medicines, Inc. 13G/A 12.99% 3y
Nantahala Capital Management, LLC RDNW RideNow Group, Inc. 13G/A 10.7% 3y
Dapice Joshua J. RVMD Revolution Medicines, Inc. 13G 6.2% 3y
First Trust Capital Management L.P. FEXD Fintech Ecosystem Development Corp. Class A Common Stock 13G/A 9.68% 3y
COMPASS GROUP LLC VTRU Vitru Limited Common Shares 13G/A 14.15% 3y
WELLINGTON MANAGEMENT GROUP LLP AGIO Agios Pharmaceuticals, Inc. 13G/A 3.95% 3y
John P. Szabo, Jr. GAIA Gaia, Inc 13G 9% 3y
Versant Venture Capital VI, L.P. BDTX Black Diamond Therapeutics, Inc. 13D/A 8.4% 3y
Versant Venture Capital VI, L.P. GLUE Monte Rosa Therapeutics, Inc. 13D/A 13.7% 3y
Versant Venture Capital VI, L.P. TPST Tempest Therapeutics, Inc. 13D/A 15.9% 3y
Versant Venture Capital VI, L.P. PASG Passage BIO, Inc. 13D/A 7.3% 3y
John P. Szabo, Jr. INVE INVE Technologies, Inc. 13G 8% 3y
TENOR CAPITAL MANAGEMENT Co., L.P. NOGN Nogin, Inc. Common Stock 13G 5.03% 3y
Jelena Puzovic ATER Aterian, Inc. 13G/A 0.07% 3y
Artisan Topco LP AVID Avid Technology Inc 13D/A 100% 3y
Exor N.V. CLVT Clarivate PLC 13D/A 7.37% 3y
Patel Chirag K. AMRX Amneal Pharmaceuticals, Inc. 13D/A 7.1% 3y
STADIUM CAPITAL MANAGEMENT LLC SNBRQ Sleep Number Corp 13D/A 9% 3y
Patel Dipan AMRX Amneal Pharmaceuticals, Inc. 13D/A 8.8% 3y
Atlas Investissement SAS TIGO Millicom International Cellular SA 13D/A 28.2% 3y
Patel Tushar Bhikhubhai AMRX Amneal Pharmaceuticals, Inc. 13D/A 17.5% 3y
Jacobsen Per A. BLIN Bridgeline Digital, Inc. 13G/A 6.5% 3y
Gautam Patel AMRX Amneal Pharmaceuticals, Inc. 13D/A 10% 3y
TORO 18 HOLDINGS LLC UEIC Universal Electronics Inc 13D/A 10.9% 3y
Patel Chintu AMRX Amneal Pharmaceuticals, Inc. 13D/A 8.3% 3y
Family Trading Inc. TOPS Top Ships Inc. 13D/A 60.79% 3y
Rubric Capital Management LP MREO Mereo BioPharma Group plc 13D/A 13.63% 3y
BRIGADE CAPITAL MANAGEMENT, LP GFR Greenfire Resources Ltd. 13D/A 8.8% 3y
Saba Capital Management, L.P. BMEZ BlackRock Health Sciences Term Trust 13D/A 11.31% 3y
Bandera Partners LLC JYNT JOINT Corp 13D/A 26.7% 3y
Saba Capital Management, L.P. SABA Saba Capital Income & Opportunities Fund II 13D/A 30.86% 3y
Peter J. Werth CING Cingulate Inc. 13D/A 19.99% 3y
Qatar Investment Authority NBTX Nanobiotix S.A. 13G 8.6% 3y
Jerome F. McAleer LMDX LumiraDx Limited Common Shares 13D/A 9.3% 3y
Bellevue Capital Partners, LLC NYC American Strategic Investment Co. 13D/A 46.3% 3y
David Scott LMDX LumiraDx Limited Common Shares 13D/A 10.8% 3y
First Frontier Capital LLC RMCO Royalty Management Holding Corp 13D 8.2% 3y
LEUTHOLD GROUP, LLC AAPD Direxion Shares ETF Trust 13G/A 13.5% 3y
White River Ventures LLC RMCO Royalty Management Holding Corp 13D 6% 3y
JPMORGAN CHASE & CO TER Teradyne, Inc 13G/A 3.7% 3y
Lumira Capital Investment Management Inc. ENGN enGene Therapeutics Inc. 13D 14.4% 3y
JPMORGAN CHASE & CO GPOR Gulfport Energy Corp 13G/A 3.8% 3y